Literature DB >> 19450750

Effect of ex vivo culture of CD34+ bone marrow cells on immune reconstitution of XSCID dogs following allogeneic bone marrow transplantation.

Douglas R Kennedy1, Kyle McLellan, Peter F Moore, Paula S Henthorn, Peter J Felsburg.   

Abstract

Successful genetic treatment of most primary immunodeficiencies or hematological disorders will require the transduction of pluripotent, self-renewing hematopoietic stem cells (HSC) rather than their progeny to achieve enduring production of genetically corrected cells and durable immune reconstitution. Current ex vivo transduction protocols require manipulation of HSC by culture in cytokines for various lengths of time depending upon the retroviral vector that may force HSC to enter pathways of proliferation, and possibly differentiation, which could limit their engraftment potential, pluripotentiality and long-term repopulating capacity. We have compared the ability of normal CD34(+) cells cultured in a standard cytokine cocktail for 18hours or 4.5 days to reconstitute XSCID dogs following bone marrow transplantation in the absence of any pretransplant conditioning with that of freshly isolated CD34(+) cells. CD34(+) cells cultured under standard gamma-retroviral transduction conditions (4.5 days) showed decreased engraftment potential and ability to sustain long-term thymopoiesis. In contrast, XSCID dogs transplanted with CD34(+) cells cultured for 18hours showed a robust T cell immune reconstitution similar to dogs transplanted with freshly isolated CD34(+) cells, however, the ability to sustain long-term thymopoiesis was impaired. These results emphasize the need to determine ex vivo culture conditions that maintain both the engraftment potential and "stem cell" potential of the cultured cells.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19450750      PMCID: PMC2684861          DOI: 10.1016/j.bbmt.2009.03.014

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  56 in total

1.  Fibroblasts retrovirally transfected with the human IL-3 gene initiate and sustain multilineage human hematopoiesis in SCID mice: comparison of CD34-enriched vs CD34-enriched and in vitro expanded grafts.

Authors:  S R Goan; K Schwarz; S von Harsdorf; C von Schilling; I Fichtner; I Junghahn; U Just; F Herrmann
Journal:  Bone Marrow Transplant       Date:  1996-09       Impact factor: 5.483

2.  Antigen CD34+ marrow cells engraft lethally irradiated baboons.

Authors:  R J Berenson; R G Andrews; W I Bensinger; D Kalamasz; G Knitter; C D Buckner; I D Bernstein
Journal:  J Clin Invest       Date:  1988-03       Impact factor: 14.808

Review 3.  CD34: structure, biology, and clinical utility.

Authors:  D S Krause; M J Fackler; C I Civin; W S May
Journal:  Blood       Date:  1996-01-01       Impact factor: 22.113

Review 4.  Severe combined immunodeficiency. A model disease for molecular immunology and therapy.

Authors:  Alain Fischer; Françoise Le Deist; Salima Hacein-Bey-Abina; Isabelle André-Schmutz; Geneviève de Saint Basile; Jean-Pierre de Villartay; Marina Cavazzana-Calvo
Journal:  Immunol Rev       Date:  2005-02       Impact factor: 12.988

5.  Dog leukocyte antigen-haploidentical stem cell allografts after anti-CD44 therapy and reduced-intensity conditioning in a preclinical canine model.

Authors:  Brenda M Sandmaier; Takahiro Fukuda; Theodore Gooley; Cong Yu; Erlinda B Santos; Rainer Storb
Journal:  Exp Hematol       Date:  2003-02       Impact factor: 3.084

6.  Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1.

Authors:  Marion G Ott; Manfred Schmidt; Kerstin Schwarzwaelder; Stefan Stein; Ulrich Siler; Ulrike Koehl; Hanno Glimm; Klaus Kühlcke; Andrea Schilz; Hana Kunkel; Sonja Naundorf; Andrea Brinkmann; Annette Deichmann; Marlene Fischer; Claudia Ball; Ingo Pilz; Cynthia Dunbar; Yang Du; Nancy A Jenkins; Neal G Copeland; Ursula Lüthi; Moustapha Hassan; Adrian J Thrasher; Dieter Hoelzer; Christof von Kalle; Reinhard Seger; Manuel Grez
Journal:  Nat Med       Date:  2006-04-02       Impact factor: 53.440

7.  The ex vivo expansion of feline marrow cells leads to increased numbers of BFU-E and CFU-GM but a loss of reconstituting ability.

Authors:  J L Abkowitz; M R Taboada; K M Sabo; G H Shelton
Journal:  Stem Cells       Date:  1998       Impact factor: 6.277

8.  Monoclonal antibodies that define canine homologues of human CD antigens: summary of the First International Canine Leukocyte Antigen Workshop (CLAW).

Authors:  S Cobbold; S Metcalfe
Journal:  Tissue Antigens       Date:  1994-03

9.  IL-2R gamma gene microdeletion demonstrates that canine X-linked severe combined immunodeficiency is a homologue of the human disease.

Authors:  P S Henthorn; R L Somberg; V M Fimiani; J M Puck; D F Patterson; P J Felsburg
Journal:  Genomics       Date:  1994-09-01       Impact factor: 5.736

10.  Gene therapy improves immune function in preadolescents with X-linked severe combined immunodeficiency.

Authors:  Javier Chinen; Joie Davis; Suk See De Ravin; Beverly N Hay; Amy P Hsu; Gilda F Linton; Nora Naumann; Effie Y H Nomicos; Christopher Silvin; Jean Ulrick; Narda L Whiting-Theobald; Harry L Malech; Jennifer M Puck
Journal:  Blood       Date:  2007-03-16       Impact factor: 22.113

View more
  9 in total

1.  GPRASP proteins are critical negative regulators of hematopoietic stem cell transplantation.

Authors:  Antonio Morales-Hernández; Chaïma Benaksas; Ashley Chabot; Claire Caprio; Maheen Ferdous; Xiwen Zhao; Guolian Kang; Shannon McKinney-Freeman
Journal:  Blood       Date:  2020-04-02       Impact factor: 22.113

2.  Ex vivo γ-retroviral gene therapy of dogs with X-linked severe combined immunodeficiency and the development of a thymic T cell lymphoma.

Authors:  Douglas R Kennedy; Brian J Hartnett; Jeffrey S Kennedy; William Vernau; Peter F Moore; Thomas O'Malley; Linda C Burkly; Paula S Henthorn; Peter J Felsburg
Journal:  Vet Immunol Immunopathol       Date:  2011-04-14       Impact factor: 2.046

Review 3.  Gene therapy studies in a canine model of X-linked severe combined immunodeficiency.

Authors:  Peter J Felsburg; Suk See De Ravin; Harry L Malech; Brian P Sorrentino; Christopher Burtner; Hans-Peter Kiem
Journal:  Hum Gene Ther Clin Dev       Date:  2015-02-24       Impact factor: 5.032

Review 4.  Update on gene therapy for immunodeficiencies.

Authors:  Donald B Kohn
Journal:  Clin Immunol       Date:  2010-01-13       Impact factor: 3.969

5.  Lentiviral transduction of CD34(+) cells induces genome-wide epigenetic modifications.

Authors:  Yoshiaki Yamagata; Véronique Parietti; Daniel Stockholm; Guillaume Corre; Catherine Poinsignon; Nizar Touleimat; Damien Delafoy; Céline Besse; Jörg Tost; Anne Galy; András Paldi
Journal:  PLoS One       Date:  2012-11-07       Impact factor: 3.240

Review 6.  Developments and translational relevance for the canine haematopoietic cell transplantation preclinical model.

Authors:  Scott S Graves; Rainer Storb
Journal:  Vet Comp Oncol       Date:  2020-05-26       Impact factor: 2.385

7.  Ex Vivo Selection of Transduced Hematopoietic Stem Cells for Gene Therapy of β-Hemoglobinopathies.

Authors:  Kanit Bhukhai; Edouard de Dreuzy; Marie Giorgi; Charlotte Colomb; Olivier Negre; Maria Denaro; Béatrix Gillet-Legrand; Joëlle Cheuzeville; Anaïs Paulard; Hélène Trebeden-Negre; Suparerk Borwornpinyo; Karine Sii-Felice; Leila Maouche; Julian D Down; Phillippe Leboulch; Emmanuel Payen
Journal:  Mol Ther       Date:  2017-10-24       Impact factor: 11.454

8.  Gene Therapy For Beta-Thalassemia: Updated Perspectives.

Authors:  Garyfalia Karponi; Nikolaos Zogas
Journal:  Appl Clin Genet       Date:  2019-09-23

Review 9.  In-Vivo Gene Therapy with Foamy Virus Vectors.

Authors:  Yogendra Singh Rajawat; Olivier Humbert; Hans-Peter Kiem
Journal:  Viruses       Date:  2019-11-23       Impact factor: 5.048

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.